Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAB Trial of tozorakimab in COPD
2025-522359-24-00Phase 2Authorised
- Sponsor
- University of Leicester
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tozorakimab with Placebo (2 arms). Primary endpoints: Improvement in epithelial remodeling histology score and Improvement in granulocytic inflammation in bronchial submucosa. Planned start Oct 2026; status: authorised.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2025-522359-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522359-24-00.